Forte Biosciences Confirms $162.1M Public Offering, Extends Cash Runway to 12+ Months

summarizeSummary

Forte Biosciences reported Q1 financials with increased R&D and net loss, but confirmed the closing of a $162.1 million public offering at a premium price, securing over 12 months of operating capital.

check_boxKey Events

• Public Offering Closed

  Confirmed the closing of a $162.1 million net proceeds public offering on April 8, 2026, which included the full exercise of the underwriters' option. The offering was priced at $26.27 per share, a premium to the current market price of $24.54.

• Extended Cash Runway

  The company now projects its existing cash and proceeds from the offering will fund operations for at least 12 months from the filing date, addressing near-term liquidity concerns.

• Increased R&D Expenses

  Research and development expenses rose to $20.5 million in Q1 2026 from $12.7 million in Q1 2025, reflecting accelerated clinical development for FB102 in celiac disease, vitiligo, and alopecia areata.

• Higher Net Loss

  Reported a net loss of $22.1 million for Q1 2026, an increase from $15.7 million in Q1 2025, driven by higher R&D costs.

auto_awesomeAnalysis

This quarterly report confirms the closing of a substantial $162.1 million public offering, which was priced at a premium to the current market price. This capital raise significantly bolsters the company's liquidity, extending its cash runway to at least 12 months, a critical factor for a clinical-stage biopharmaceutical company. While the company reported increased net losses and cash burn in Q1 2026 due to accelerated R&D for its FB102 clinical trials, the successful financing provides necessary capital to advance its pipeline in celiac disease, vitiligo, and alopecia areata.